Artiva Biotherapeutics
IPONK Cell Therapy for Autoimmune Disease and Cancer
Public · United States
- Business Model
- B2B
- Website
- artivabio.com
- Last Round
- Series BFeb 2021
- Rounds
- 3
- Type
- Public
About
Clinical-stage biotech developing AlloNK, an allogeneic NK cell therapy for autoimmune disease and cancer.
Summary
Artiva Biotherapeutics is a Biotech company based in United States. Its most recent funding was a Series B round in Feb 2021. Investors include venBIO Partners, Venrock and 5AM Ventures.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
May 2026
Sign up to see all 5 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...